12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Subcutaneous beloranib: Interim Phase IIa data

Data from a pre-specified interim analysis of the first 19 obese patients who completed 12 weeks of treatment in a double-blind, Australian Phase IIa trial showed that twice-weekly 0.6, 1.2 and 2.4 mg subcutaneous beloranib each led to significantly greater mean weight loss from baseline to week 12 vs. placebo. Specifically, low-dose beloranib led to a mean weight loss of 3.8 kg, mid-dose beloranib led to a mean weight loss of...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >